ClinicalTrials.gg
RecruitingNCT06622434NAVIG-1Updated Jun 11, 2026

New Adjuvant Vaccine in Glioblastoma, a Phase 1/2a Study

A Phase 1/2 interventional study of immunization in Newly Diagnosed Glioblastoma, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 3 sites in France. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Assistance Publique - Hôpitaux de Paris · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2024; still recruiting 2 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris — 2 open to participants now, 2 under way, none of them phase 3. Glioblastoma · Assistance Publique - Hôpitaux de Paris.

Started
2024
the only one that year
Phase 1/2
3 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris, this one is the only one that started in 2024, is one of 3 in phase 1/2, and was the 10th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

2 of the 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Glioblastoma by Assistance Publique - Hôpitaux de Paris, or all of them as a file.
02

Study summary

This phase I/II trial evaluates the safety and the immunological efficacy of a cancer vaccine against 2 glioma-associated antigens in newly-diagnosed glioblastomas.

The objectives of this study are as follows:

Primary objective

  • phase 1:
  • to assess the maximum tolerated dose (MTD) and select the recommend Phase 2a dose
  • phase 2a:
  • to assess anti- TERT specific T cell responses at 2 months at the selected dose level

Secondary objectives:

  • To assess Short and long-time immunological safety
  • To assess Evolution of anti-PTPRZ1 and anti-TERT immune T cell responses over time
  • To assess Progression free survival (RANO 2.0 criteria)
  • To assess Overall survival
  • To assess Quality of life by EORTC QLQ30 and BN20 questionnaires
  • To evaluate cardiac safety and monitor for the potential development of anti-melanin antibodies in a cohort of 8 patients enrolled in the Phase 2a study

as well as objective of ancillary study: to determine the mechanism of action of potential tumour escape in GBM (T-cell lymphocyte phenotype; antigen expression and checkpoint inhibitors on tumour cells at relapse, if available), analysis of circulating antibodies against TERT epitope and/or melanin, and identification of predictive biomarkers of response.

Ultimately, this trial together will lead to the implementation of future phase III trial in GBM.

All patients enrolled in the study will receive standard treatment consisting of surgical resection of the tumor followed by radio-chemotherapy. Immunotherapy will begin 4 weeks after the completion of radiotherapy.

Read the detailed description

Prospective multicentre Phase I- IIa, non-comparative, non-randomised study with escalating doses for the Phase 1 part.

Therapeutic cancer vaccines consisting of 1 or 2 antigenic peptidic formulations combined with an immune adjuvant:

  • A52-Mel: a TERT peptidic epitope adsorbed on synthetic melanin
  • A49-Mel: a PTPRZ1 peptidic epitope adsorbed on synthetic melanin (Phase 1 only)
  • Litenimod, a TLR9 agonist, as an adjuvant

Phase 1: Patients will receive subcutaneous injections in the shoulders of both A49 and A52 at one of 3 pre-specified dose levels of peptides (50-100-250µg) + 1mg of Litenimod (fixed dose).

Phase 2a: Patients will receive subcutaneous injections in the shoulder of A52 only at the dose selected in the phase 1 part + 1mg of Litenimod

03

Conditions studied

  • Newly Diagnosed Glioblastoma

Browse trials for

Keywords

  • Cancer vaccine
  • Glioblastoma
  • Telomerase
  • TERT
  • PTPRZ1
  • Immunomodulation
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • age between 18 and 75 years old
  • free, informed and written consent signed
  • confirmed glioblastoma
  • Patients previously treated with concurrent radiotherapy (at least 45 Gy) with concomitant temozolomide, before the beginning of the 6 additional monthly cycles of temozolomide. Radiation therapy must have been completed 28 to 45 days prior to the first study treatment
  • Performance Status ≥ 60%
  • Phase 1 only: Patients must be human leukocyte antigen (HLA)-A2 positive.
  • Phase 1 only: PTPRZ1 expression in the tumor
  • Available tumor tissue for post hoc (retrospective) assessment of TERT promoter mutations and MGMT promoter methylation status
  • ≥ 3 months
  • Adequate organ function laboratory values within 15 days before initiation of treatment (see table in section 6.1)
  • Women or Male of (WOCBP) must use methods during and for 180 days after the last dose of temozolomide or up to 120 days after the last dose of vaccine, whichever is longer (see section 6.3). No sperm donation during the study and until 7 months after the end of the treatment period.
  • Patient affiliated to the social security scheme

Exclusion criteria

Exclusion Criteria:

  • Known extracranial or
  • Grade 4 astrocytoma IDH mutant
  • requirement >10 mg prednisone daily (or equivalent) at time of inclusion
  • Patients with prior active within the last 3 years
  • Patients receiving immunomodulatory or therapy
  • Carmustine wafers (GliadelR) implantation during surgery
  • Phase 1 only: patient eligible and willing to be treated with Optune (TTF fields)
  • History of disease (lupus, rheumatoid arthritis, inflammatory bowel disease...)
  • Previous treatment with bevacizumab or other Vascular Endothelial Growth Factor (VEGF) antagonists
  • Patient with any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study.
  • Uncontrolled active systemic fungal, bacterial, viral, or other infection within the previous 4 weeks or requirement for intravenous (IV) antibiotics within the last two weeks
  • Breast-feeding or pregnant women.
  • to IRM
  • Contra-indications to medicinal product and/or to auxiliary medicinal products
  • Participation to another interventional clinical trial, clinical investigation or another interventional study or being in the exclusion period at the end of a previous study
  • Patient unable to follow the procedures and constraints of the protocol
  • Patient under legal protection (protection of the court, or in curatorship or guardianship).
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    A52-Mel; A49-Mel (for Phase1 only) and Litenimod, as an adjuvant

    In Phase 1, A52-Mel and A49-Mel will be mixed just prior to the injection. Litenimod will be injected at the same site just after the injection. In phase 2a, A52-Mel was initially administered as a standalone injection, followed by Litenimod at the same injection site. Then, an optimized procedure allows the injection of A52-Mel and Litenimod simultaneously, the two components being mixed extemporaneously prior to the injection.

    Biological: immunization

Interventions

  • Biologicalimmunization

    One month after glioblastoma patients have completed the initial phase of treatment with concurrent radiochemotherapy, patients will be immunized during the adjuvant phase of monthly temozolomide (5 days per month for 6 months). Immunizations will follow the standard schedule of a priming phase (D0, W2, W4, and W6) followed by a boost phase with one immunization every 2 months until progression, unacceptable toxicity, withdrawal of consent, or study end (at 12 months), whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Maximum tolerated dose (MTD) for Phase 1

    the maximum tolerated dose (MTD) based on the occurrence of dose limiting toxicity (DLT)

    Time frame: 2 months

  2. anti-TERT specific T cell responses (safety/efficay) for Phase 2

    anti-TERT specific T cell responses by using IFN-gamma ELISPOT

    Time frame: 2 months

Secondary outcomes

  1. Evolution of anti-PTPRZ1 specific T cell responses

    anti-PTPRZ1 specific T cell responses by using IFN-gamma ELISPOT

    Time frame: over time

  2. Overall survival

    The time interval from the start of treatment to the date of death from any cause.

    Time frame: 12 months

  3. Progression free survival

    Tumor response will be assessed using RANO 2.0 criteria

    Time frame: 12 months

  4. the evaluation of quality of life

    EORTC-QLQC30 questionnaire and BN20 module will be completed by each patient (Not all= 1; A little=2; Quite a bit= 3 ; Very Much=4)

    Time frame: 5 months

  5. Circulating anti-melanin antibodies

    in a cohort of 8 patients enrolled in the Phase 2a study

    Time frame: At M2

  6. Cardiac safety

    evaluated through 12-lead ECG assessments prior to injection, 3 hours post-injection, Day 7, Week 2, and Month 2), with a focus on QT-interval measurement. Additionally, cardiac biomarkers including troponin and pro-BNP will be monitored at baseline (Day 0), Week 2, and Month 2. assessed using 12-lead ECGs performed 3 hours after injection, on day 7, at week 2 and at

    Time frame: At month 2

07

Study locations

2 of 3 sites recruiting
  • Department of Neurology, Hopital de la Salpêtrière
    Paris, Idf 75013, France
    Recruiting
  • Neuro-oncology Department, La Timone Hospital
    Marseille, Provence-Alpes-Côte d'Azur Region 13005, France
    Not yet recruiting
  • Department of Neurology, Hopital Saint louis (APHP)
    Paris, 75010, France
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2024 (actual). Primary completion is estimated for Mar 2028, 40 months after the start.

Of 85 non-industry phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 105. This study's planned 40 months is below that.

Counting every sponsor, half of 137 studies reached it within 66 months; a quarter within 45 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2024
First posted
Oct 2, 2024
StartActual
Nov 8, 2024
Primary completionEst.
Mar 8, 2028
CompletionEst.
Mar 8, 2028
Last update
Jun 11, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06622434
Collaborators
ALTEVAX SAS
Responsible party
Sponsor
First posted
Oct 2, 2024
Start date
Nov 8, 2024
Primary completion
Mar 8, 2028 (estimated)
Completion
Mar 8, 2028 (estimated)
Last update
Jun 11, 2026

Study contacts

Antoine CARPENTIER, Pr
Contact
antoine.carpentier@aphp.fr
0171207466
Antoine CARPENTIER, Pr
study chair · APHP- Hôpital Saint Louis

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion